



Angiogenesis and Inflammation in Biological Barriers

Guest Editor:

Dr. Nadia Alfaidy

Biology and Biotechnology for
Health, Biosanté, INSERM U1292,
Grenoble, France

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

Biological barriers are essential for the integrity and proper function of many vertebrate organs and are critical for the regulation of tissue homeostasis and protection against pathogens or other tissue-damaging agents. BB separate internal and external compartments and are formed by specialized cell types, such as epithelial and endothelial cells, that interface the body and the external environment. Processes such as vascularization, angiogenesis, and inflammation play major roles in the control of the integrity of these barriers. Specialized pro- and anti-angiogenic and inflammatory factors control these processes. The latter includes the inflammasome family. Recent studies have also reported the involvement of new factors that control both angiogenic and inflammatory processes, such as the prokineticin family. Failure in the expression of these factors and/or impaired epithelial–endothelial barrier function are major hallmarks of several barrier-associated pathologies. This Special Issue welcomes original articles and reviews focused on angiogenesis and inflammation in highly vascularized biological barriers.

Dr. Nadia Alfaidy

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)